Barnidipine

Drugs

Volumn 61, Issue 7, 2001, Pages 989-996

  Malhotra, H S ^a   Plosker, G L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MEPIRODIPINE; NITRENDIPINE; YM 097305;

CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; EDEMA; HEADACHE; HUMAN; HYPERTENSION; RECEPTOR BINDING; REVIEW; STRUCTURE ANALYSIS;

EID: 0034979129     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161070-00007     Document Type: Review

References (29)

1. British Hypertension Society guidelines for hypertension management 1999: Summary
2. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension
3. How to use calcium antagonists in hypertension: Putting the JNC-VI guidelines into practice
4. A sustained occupancy in vivo of cardiovascular calcium antagonist receptors by mepirodipine and its relation to pharmacodynamic effect in spontaneously hypertensive rats
5. Correlation between the plasma concentration of mepirodipine and its occupancy of Ca2+ antagonist receptors in rats
6. In vitro and in vivo vasodilatory activity of barnidipine and its enantiomers
7. Differential time course of the vasodilator action of various calcium antagonists
8. The role of renal hemodynamics in the antihypertensive action of mepirodipine, a new calcium antagonist
9. Distinct vasodilation, without reflex neurohormonal activation, induced by barnidipine in hypertensive patients
10. Natriuretic effect of barnidipine, a long-acting dihydropyridine calcium channel blocker, in patients with essential hypertension
11. Reconsideration of vascular selectivity of dihydropyridine calcium antagonists: Comparison of cardiovascular profile of mepirodipine, a novel dihydropyridine consisting of a single stereoisomer with (+)-(S)-(S) conformation, with those of nifedipine and nicardipine
12. Effects of barnidipine hydrochloride, a calcium channel blocker, on renal microcirculation in rats: A pilot study
13. Treatment with a Ca(2+) channel blocker, barnidipine, reduces platelet-derived growth factor B-chain mRNA in glomeruli of spontaneously hypertensive rats
14. Effect of the vasodilatory beta-blocker, nipradilol, and Ca-antagonist, barnidipine, on insulin sensitivity in patients with essential hypertension
15. A review on barnidipine: A novel calcium antagonist
16. Metabolism and pharmacokinetics of barnidipine hydrochloride, a calcium channel blocker, in man following oral administration of its sustained release formulation
17. Metabolism of barnidipine hydrochloride, a potent calcium antagonist, in rat and dog
18. Examination of metabolic pathways and identification of human liver cytochrome P450 isozymes responsible for the metabolism of barnidipine, a calcium channel blocker
19. Barnidipine, a novel calcium antagonist for once-daily treatment of hypertension: A multicenter, double-blind, placebo-controlled, dose-ranging study
20. The long-term efficacy and safety profile of barnidipine
21. Evaluation of the antihypertensive effect of barnidipine, a dihydropyridine calcium entry blocker, as determined by the ambulatory blood pressure level averaged for 24h, daytime, and nighttime
22. Impact of barnidipine on 24-hour ambulatory blood pressure in patients with mild to moderate esential hypertension
23. Antihypertensive efficacy and tolerability of barnidipine hydrochloride in patients with renal parenchymal hypertension
24. Efficacy and tolerability of once-daily barnidipine in the clinical management of patients with mild to moderate essential hypertension
25. The role of combination therapy in the treatment of hypertension
26. Treatment of hypertension in the very old
27. Barnidipine monotherapy and combination therapy in older patients with essential hypertension: A long-term study
28. Diversity and intensity of adverse events in the treatment of hypertension with barnidipine